Scientists have shown for the first time that tumour DNA shed into the bloodstream can be used to track cancers in real time as they evolve and respond to treatment, according to a new Cancer Research UK study published in the journal Nature Communications.
Over three years, researchers at the University of Cambridge took surgical tumour samples (biopsies) and blood samples from a patient with breast cancer that had already spread to other parts of her body. They carefully studied small fragments of DNA from dying tumour cells that are shed into the blood, comparing them with DNA from the biopsy that was taken at the same point in time.
The results show that the DNA in the blood samples matched up with that from the biopsies, reflecting the same pattern and timing of genetic changes appearing as the cancer developed and responded to treatment. The results provide the first proof-of-principle that analysing tumour DNA in the blood can accurately monitor cancer within the body.
Study author Professor Carlos Caldas, senior group leader at the Cancer Research UK Cambridge Institute, said: “This definitively shows that we can use blood-based DNA tests to track the progress of cancer in real time. The findings could change the way we monitor patients, and may be especially important for people with cancers that are difficult to reach, as taking a biopsy can sometimes be quite an invasive procedure.”
The patient in the study had breast cancer that had already spread to a number of other organs. The researchers – part of a collaborative team effort involving the Carlos Caldas and Nitzan Rozenfeld laboratories at the Cancer Research UK Cambridge Institute – were even able to distinguish between the different secondary cancers and examine how each of the tumours was responding to treatment.
Professor Caldas added: “We were able to use the blood tests to map out the disease as it progressed. We now need to see if this works in more patients and other cancer types, but this is an exciting first step.”
The Latest on: Track cancer development
via Google News
The Latest on: Track cancer development
- Lung Cancer Drugs Market Report Analysis, Share, Revenue, Growth Rate With Forecast Overview To 2025on June 25, 2020 at 5:32 am
Global Lung Cancer Drugs Market - Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025[93 pages report] ...
- Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-Lon June 23, 2020 at 5:30 am
Polynoma LLC, a U.S. immuno-oncology focused biopharmaceutical company and wholly-owned subsidiary of Hong Kong-listed CK Life Sciences Int'l., (Holdings) Inc., announces that the U.S. Food and Drug ...
- Ipsen scores FDA fast-track for Onivyde in first-line pancreatic canceron June 19, 2020 at 3:31 am
The fast-track programme aids the development and also expedites the review of drugs that are designed to treat serious medical conditions and have the potential to address an unmet medical need.
- Chi-Med Announces Fruquintinib Granted U.S. FDA Fast Track Designation for Metastatic Colorectal Canceron June 18, 2020 at 12:15 am
Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation for the development of ...
- Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Canceron June 17, 2020 at 1:32 pm
Lassen Therapeutics, a biotech that is developing antibodies as potential treatments for fibrosis, rare diseases, and cancer, debuted Wednesday with $31 ...
- Nanobiotix Receives Feedback From US FDA to Advance Phase III Head and Neck Cancer Study Design and CMC Development Plan for NDAon June 17, 2020 at 10:25 am
With our recent Fast Track designation for NBTXR3 in this patient population, acceptance of the design of our pivotal ...
- Ipsen Receives FDA Fast Track Designation For Liposomal Irinotecanon June 16, 2020 at 10:46 pm
(RTTNews) - Ipsen (IPSEY) said that the United States Food and Drug Administration has granted the company Fast Track designation for the investigational use of liposomal irinotecan or ONIVYDE in ...
- Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as a First-Line Combination Treatment for Metastatic Pancreatic Canceron June 16, 2020 at 10:19 pm
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the United States Food and Drug Administration (FDA) has granted the ...
- Small Molecule Cancer Inhibitors May Suppress Growth in Some Drug Resistant Tumorson June 16, 2020 at 1:00 pm
City of Hope scientists have identified and developed two potent small molecules that appear to suppress tumor growth in multiple cancers even when other treatments cease to work, possibly due to the ...
- 2 Top Cancer Treatment Stocks to Buy in Juneon June 16, 2020 at 8:09 am
June holds plenty of catalysts for biotechnology stocks -- especially those specializing in cancer treatments. Investors with extra cash on the sidelines may be able to capture some exciting cancer ...
via Bing News